What the business is, and whether it's a good one at a fair price.
Operates a pan-India diagnostic testing business, running pathology and preventive-health tests through 43 Indian labs and one lab in Tanzania, processing 55.2 million tests for 5.4 million patients in Q1 FY27. The core Diagnostic Testing Services segment generated ₹772.53 crore in FY26, or 93.2% of segment revenue, and ₹197.48 crore of EBIT, driven by branded wellness packages (Aarogyam, Jaanch), routine pathology, and a B2B network of 11,700 active franchisees fed via channel partners. Imaging Services, which runs PET-CT and CT centres and makes radiopharmaceuticals through subsidiary Nueclear Healthcare, contributed ₹53.14 crore (6.4% of segment revenue) and just ₹0.67 crore of EBIT; the board has approved evaluating its demerger or sale, expected over ~6 months. The cost stack is dominated by materials (26.4% of revenue) and employee costs (16.7%), with depreciation at 7.1% and capex at 2.5% of revenue, reflecting a hub-and-spoke processing model rather than a heavy-asset footprint. A new specialty diagnostics line in genomics and allergy was commercially launched in Q1 FY27, with management targeting 15–20% of the portfolio over 3–5 years.
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from THYROCARE TECH LTD's filed financials and exchange disclosures
THYROCARE TECH LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol THYROCARE.
Yes. Over the trailing twelve months THYROCARE TECH LTD reported a net profit of ₹176 Cr on revenue of ₹876 Cr.
Yes. The dividend yield is 1.69% at the current price. It paid out 91% of its profit as dividend in FY26.
Effectively yes. It holds ₹38 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, THYROCARE TECH LTD ranks 18 of 29 in Healthcare Service Provider — cheaper than 39% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
On a typical session THYROCARE TECH LTD moves 1.53% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by THYROCARE TECH LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
